Skip to main content

Specialty Pharmacy

  • FDA approves biotech drug for reducing symptoms of severe chickenpox infection

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for reducing the severity of chickenpox symptoms, the agency said Friday.

    The FDA announced the approval of Cangene Corp.'s Varizig (varicella zoster immune globulin [human]) for varicella zoster, the virus that causes chickenpox. The FDA said Varizig was the only FDA-approved immune globulin for the virus after exposure.

  • Advocacy group says proposed compounding regulations would endanger public health

    WASHINGTON — An advocacy group said proposed Food and Drug Administration rules for compounding pharmacies would put the public's health and safety at risk.

    In a letter sent to Department of Health and Human Services secretary Kathleen Sebelius, Public Citizen criticized Food and Drug Administration commissioner Margaret Hamburg for "both undermining her agency's authority in congressional testimony last month and offering a plan that would effectively weaken the agency's oversight of drug manufacturing."

  • Study finds increase in retail co-pays for prescription drugs

    PLANO, Texas — Retail co-pays for drugs are on the rise across all drug types, according to a new study by the Pharmacy Benefit Management Institute.

    The study, based on a survey of 424 U.S. employers representing about 3.7 million members, found that retail co-pays increased 10% for generics, 13% for branded drugs and 26% for specialty drugs. Meanwhile, there was an increase in use of multitier designs, which now represent 92% of plan sponsors, while adoption of medication therapy management for commercial populations was "minimal."

  • Symposium brings together specialty pharmacy stakeholders

    PHILADELPHIA — The changing healthcare environment and the challenges and opportunities of specialty pharmacy were the biggest themes at Acro Pharmaceutical Services' sixth annual Payer and Managed Care Symposium in Philadelphia last Thursday.

    Representatives from drug makers and across the specialty pharmacy space met at the Hyatt at the Bellevue to discuss a wide variety of topics related to specialty pharmacy.

  • FDA approves generic HIV drug

    SILVER SPRING, Md. — The Food and Drug Administration has approved two generic versions of a drug to treat HIV, according to agency records.

    The FDA approved abacavir sulfate tablets in the 300-mg strength made by Apotex and Aurobindo.

    The drug is a generic version of Viiv Healthcare's Ziagen.


    Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

  • Maddak introduces Built-Up Handle for arthritis sufferers

    WAYNE, N.J. — A new product makes gripping such things as eating utensils, pens and toothbrushes easier for people with arthritis.

    Maddak announced the availability of the Universal Built-Up Handle, designed as a "do-it-yourself" product to enlarge the gripping surfaces of common household items.

  • Most prescribers would pick biosimilar RA drugs

    BURLINGTON, Mass. — A majority of prescribers would prescribe biosimilar versions of two treatments for rheumatoid arthritis within a year of their approval, according to a new study.

  • FDA approves GlaxoSmithKline's raxibacumab for anthrax

    LONDON — The Food and Drug Administration has approved a new biotech drug from GlaxoSmithKline for anthrax, the drug maker said.

    GSK announced the approval of raxibacumab for adults and children who have inhaled Bacillus anthracis. The drug is designed for combination with antibiotics and for preventing inhalational anthrax when alternative therapies aren't available. The drug is the result of a project that Human Genome Sciences, now owned by GSK, began working on in 2001 in response to terrorist anthrax attacks in the United States.

X
This ad will auto-close in 10 seconds